Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01056107 · ClinicalTrials.gov registry record · Phase 1
Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients
A Phase 1 study of Irritable Bowel Syndrome Constipation Predominant, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT01056107 is a Phase 1 study of Irritable Bowel Syndrome Constipation Predominant that has completed, run by Mayo Clinic. The registered enrollment target is 52 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01056107, a Phase 1 study of Irritable Bowel Syndrome Constipation Predominant, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will study the effects of an investigational (not FDA approved) medication, ROSE-010, on the movement of food through the stomach, small intestine and colon in females with constipation predominant irritable bowel syndrome (C-IBS). The study hypothesis is that ROSE-010 will delay gastric emptying of solids and enhances gastric accommodation without retarding colonic transit in female patients with C-IBS.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ROSE-010
Study Locations (1)
Minnesota
- Mayo Clinic Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01056107
The ClinicalTrials.gov registry entry for NCT01056107 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Irritable Bowel Syndrome Constipation Predominant appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01056107 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT01056107 about?
NCT01056107 is a clinical study titled "Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients". This trial will study the effects of an investigational (not FDA approved) medication, ROSE-010, on the movement of food through the stomach, small intestine and colon in females with constipation predominant irritable bowel syndrome (C-IBS). The study hypothesis is that ROSE-010 will delay gastric...
What is the current status of trial NCT01056107?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2010-01. Estimated completion is 2011-12.
What conditions does trial NCT01056107 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome Constipation Predominant.
What interventions are being tested in trial NCT01056107?
The interventions under investigation include: Placebo (DRUG), ROSE-010 (DRUG).
Who is sponsoring clinical trial NCT01056107?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01056107 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.